Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020.
Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry.
Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the biosimilars market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market.
Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.
Key Benefits
Key Deliverables
Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography.
MARKET BY TECHNOLOGY
MARKET BY TYPES
MARKET BY APPLICATIONS
MARKET BY SERVICES
MARKET BY GEOGRAPHY
CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segment
1.3 Key Audiences
1.3.1 Research Methodology
1.3.2 Primary Research
1.3.3 Secondary Research
1.3.4 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of biosimilar drugs
3.4 Key Findings
3.4.1 Top factors impacting Biosimilars/Follow-On-Biologics market
3.4.2 Top winning strategies in the Biosimilars/Follow-On-Biologics market
3.4.3 Top investment pockets in Biosimilars/Follow-On-Biologics market
3.5 Regulation and Reimbursement scenario
3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines
3.6 Emerging economies a hotspot for biosimilars market
3.6.1 “Brazil” a treasure for the biosimilar manufacturers
3.6.2 “China” the dragon market for biosimilars
3.6.3 “India” an early adopter of biosimilars
3.7 Porters five force analysis
3.7.1 Moderate bargaining of suppliers due to moderate switching cost
3.7.2 Moderate bargaining power of buyers due to lesser cost of switching
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players
3.8 Value chain analysis
3.8.1 Primary activities
3.8.2 Impact analysis of stakeholders involved in primary activities (2014-2020)
3.8.3 Supportive activities
3.9 Clinical trials
3.9.1 Title: Efficacy Study of Two Formulations of Erythropoietin
3.9.2 Title: Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.3 Title: MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.4 Title: An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
3.10 Market Share analysis, 2013
3.11 Market Dynamics
3.11.1 Drivers
3.11.1.1 Growing pressure to reduce healthcare expenditure
3.11.1.2 Various blockbusters going off patent
3.11.1.3 High prevalence of chronic diseases among ageing population
3.11.1.4 Favorable intervention from the developing economies
3.11.1.5 Lower cost biosimilars drugs than original biologics
3.11.2 Restraints
3.11.2.1 High initial investment in research and development
3.11.2.2 Stringent regulations in developed economies to restrict investment
3.11.2.3 Medical Efficacy and Patient Safety
3.11.3 Opportunities
3.11.3.1 opportunities in Emerging economies
3.11.3.2 Emergence of bio-betters drugs
CHAPTER 4 GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY
4.1 Monoclonal Antibodies (MAb) Technology
4.1.1 Drivers
4.2 Recombinant DNA Technology (rDNA technology)
4.2.1 Drivers
4.2.2 Restraints & Opportunities
4.3 Chromatography
4.3.1 Drivers & Opportunities
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Protein sequencing
4.3.5 Drivers
4.4 Nuclear magnetic resonance (NMR) technology
4.4.1 Drivers
4.5 Electrophoresis
4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis
4.6 MASS SPECTROMETRY
4.6.1 DRIVERS
4.6.2 RESTRAINTS
4.7 Western Blotting
4.7.1 Drivers
4.8 Bioassay
4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay
4.8.3.1 Multiple Point Assays
4.8.3.2 Interpolation Method
4.8.3.3 Bracketing Method
4.8.3.4 Matching Bioassays
CHAPTER 5 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE
5.1 Recombinant Non-Glycosylated Protein
5.1.1 Drivers
5.1.2 Human Growth Hormone
5.1.2.1 Key market trends
5.1.2.2 Key growth factors and opportunities
5.1.2.3 Market size & forecast
5.1.3 Insulin
5.1.3.1 Drivers & Opportunities
5.1.3.2 Key market trends
5.1.3.3 Key growth factors and opportunities
5.1.3.4 Market size & forecast
5.1.4 Interferon
5.1.4.1 Interferon Alfa
5.1.4.2 Interferon beta-1a
5.1.4.3 Interferon gamma
5.1.4.4 Key growth factors and opportunities
5.1.4.5 Market size & forecast
5.1.5 Granulocyte colony stimulating factor (G-CSF)
5.1.5.1 Key market trends
5.1.5.2 Market size & forecast
5.1.6 Others
5.1.6.1 Lepirudin
5.1.6.2 Interleukin – 2 (IL-2)
5.1.6.3 Anakinra
5.2 Recombinant Glycosylated Proteins
5.2.1 Drivers & Restraints
5.2.2 Erythropoietin
5.2.2.1 Key market trends
5.2.2.2 Key growth factors and opportunities
5.2.2.3 Market size & forecast
5.2.3 Monoclonal antibodies
5.2.3.1 Key market trends
5.2.3.2 Key growth factors and opportunities
5.2.3.3 Market size & forecast
5.2.4 Others
5.2.4.1 Follitropin
5.2.4.2 Thyrotropin
5.2.4.3 Urokinase
5.2.4.4 Glucocerebrosidase
5.2.4.5 Becaplermin
5.2.4.6 Factor VIIa
5.2.4.7 Factor VIII
5.2.4.8 Factor IX
5.2.5 Key market trends
5.2.6 Competitive scenario
5.3 Peptide s
5.3.1 Drivers
5.3.2 Restraints & Opportunities
5.3.3 Octreotide
5.3.4 Desmopressin
5.3.5 Cyclosporine
5.3.6 Calcitonin
5.3.7 Eptifibatide
5.3.8 LH-RH (Leuprolide)
5.3.9 Nesiritide
5.3.10 Teriparatide
5.3.11 Bivalirudin
5.3.12 Enfuvirtide
5.3.13 Glucagon
CHAPTER 6 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS
6.1 Blood disorders
6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia
6.1.2.1 Drivers
6.1.2.2 RESTRAIN AND OPPORTINITIES
6.1.3 Hemophilia
6.1.4 Pulmonary embolism
6.1.4.1 DRIVER
6.2 Oncology diseases
6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Colorectal cancer
6.2.5 Breast cancer
6.2.6 Cervical cancer
6.2.7 Leukemia
6.2.7.1 Drivers
6.2.8 Prostate cancer
6.3 Chronic and autoimmune diseases
6.3.1 Diabetes
6.3.1.1 Drivers
6.3.2 Neutropenia
6.3.3 Multiple sclerosis
6.3.3.1 Drivers
6.3.3.2 Restraints and opportunities
6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA)
6.3.5.1 Drivers
6.3.5.2 Restraints
6.3.6 Acromegaly
6.3.6.1 Drivers
6.3.7 Leprosy
6.4 Growth hormone deficiency
6.4.1 Drivers
6.5 Others
6.5.1 Gaucher disease
6.5.2 Osteoporosis
CHAPTER 7 GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES
7.1 Contract Research and Manufacturing Services
7.1.1 Drivers
7.1.2 Restraints & Opportunities
7.2 Clinical trials
7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
CHAPTER 8 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES
8.1 North America
8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast
8.2 Europe
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast
8.3 Asia-Pacific
8.3.1 Key market trends
8.3.1.1 India
8.3.1.1.1 COMPETITIVE SCENARIO
8.3.1.2 China
8.3.1.2.1 COMPETITIVE SCENARIO
8.3.1.3 Australia
8.3.1.3.1 COMPETITIVE SCENARIO
8.3.2 Market size & forecast
8.4 LAMEA
8.4.1 Key market trends
8.4.2 Competitive scenario
8.4.3 Market size & forecast
CHAPTER 9 KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY
9.1 US
9.1.1 Hospira
9.1.1.1 Recent Activities
9.2 Europe
9.2.1 Stada Arzneimittel AG
9.2.1.1 Recent Activities
9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton
9.2.4.1 Recent Activities
9.2.5 Sandoz GmbH
9.2.5.1 Recent Activities
9.3 India
9.3.1 Dr.Reddy's Labs (DRL)
9.3.1.1 Recent Activities
9.3.2 Intas Pharmaceuticals Ltd.
9.3.2.1 Recent Activities
9.3.3 Wockhardt Limited
9.3.3.1 Recent Activities
9.3.4 Biocon Limited
9.3.4.1 Recent Activities
9.3.5 Shantha Biotechnics Limited
9.3.5.1 Recent Activities
9.3.6 Reliance Life Sciences
9.4 Korea
9.4.1 Dong-A Pharmaceutical Co., Ltd
9.4.1.1 Recent Activities
9.4.2 LG Life Sciences
9.4.2.1 Recent Activities
9.4.3 Celltrion Pharm, Inc.
9.4.3.1 Recent Activities
9.5 Others
9.5.1 Teva Pharmaceutical Industries Ltd.
9.5.1.1 Recent Activities
CHAPTER 10 COMPANY PROFILES
10.1 Novartis (Sandoz)
10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Business Performance
10.1.4 Key Strategies
10.1.4.1 Primary Strategies: Clinical Trials
10.1.4.2 secondary Strategies: approval
10.1.5 SWOT analysis
10.2 Synthon Pharmaceuticals, Inc.
10.2.1 Company Overview
10.2.2 Company Snapshot
10.2.3 Key Strategies
10.2.3.1 Primary Strategies: agreement
10.2.3.2 secondary Strategies: clinical trials
10.2.4 SWOT analysis
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Business Performance
10.3.4 Key Strategies
10.3.4.1 Primary Strategies: approval
10.3.4.2 secondary Strategies: clinical trials
10.3.5 SWOT analysis
10.4 LG Life Sciences
10.4.1 Company Overview
10.4.2 Company Snapshot
10.4.3 Business Performance
10.4.4 Key Strategies
10.4.4.1 Primary Strategies: Collaboration
10.4.5 SWOT analysis
10.5 Celltrion
10.5.1 Company Overview
10.5.2 Company Snapshot
10.5.3 Business Performance
10.5.4 Key Strategies
10.5.4.1 Primary Strategies: approval
10.5.5 SWOT analysis
10.6 Biocon
10.6.1 Company Overview
10.6.2 Company Snapshot
10.6.3 Business Performance
10.6.4 Key Strategies
10.6.4.1 secondary Strategy: clinical trial
10.6.5 SWOT analysis
10.7 Hospira
10.7.1 Company Overview
10.7.2 Company Snapshot
10.7.3 Business Performance
10.7.4 Key Strategies
10.7.4.1 Primary Strategies: approval
10.7.4.2 secondary Strategies: clinical trials
10.7.5 SWOT analysis
10.8 Merck Serono (Merck Group)
10.8.1 Company Overview
10.8.2 Company Snapshot
10.8.3 Business Performance
10.8.4 Key Strategies
10.8.4.1 Primary Strategies: partnership and product launch
10.8.5 SWOT analysis
10.9 Biogen idec Inc.
10.9.1 Company Overview
10.9.2 Company Snapshot
10.9.3 Business Performance
10.9.4 Key Strategies
10.9.4.1 Primary Strategies: agreement and joint venture
10.9.5 SWOT analysis
10.10 Genentech (Roche Group)
10.10.1 Company Overview
10.10.2 Company Snapshot
10.10.3 Key Strategies
10.10.3.1 Primary Strategies: Investment and license
10.10.4 SWOT analysis
LIST OF TABLES
TABLE 1 BLOCKBUSTER PATENTS EXPIRATION BY 2014
TABLE 2 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 5 BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
TABLE 6 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
TABLE 7 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
TABLE 8 OFF GOING PATENTS 2013-2016
TABLE 9 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
TABLE 10 BIOSIMILAR DEVELOPMENT STATUS (2013)
TABLE 11 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
TABLE 12 GLOBAL NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
TABLE 13 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
TABLE 14 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
TABLE 15 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 16 PATENTS APPROVED FOR INSULIN (BIOLOGICS)
TABLE 17 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 18 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
TABLE 19 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
TABLE 20 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 21 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
TABLE 22 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 23 GLOBAL OTHER NON-GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 24 GLOBAL GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2013-2020 ($MILLION)
TABLE 25 PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
TABLE 26 PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
TABLE 27 GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 28 DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
TABLE 29 PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING 2014-2020 (BIOLOGICS)
TABLE 30 GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 31 GLOBAL OTHER GLYCOSYLATED PROTEIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 32 GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY TYPES 2013-2020 ($MILLION)
TABLE 33 GLOBAL OCTREOTIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 34 GLOBAL DESMOPRESSIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 35 GLOBAL CYCLOSPORINE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 36 GLOBAL CALCITONIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 37 GLOBAL EPTIFIBATIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 38 GLOBAL LH-RH (LEUPROLIDE)PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 39 GLOBAL NESIRITIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 40 GLOBAL TERIPARATIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 41 GLOBAL BIVALIRUDIN PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 42 GLOBAL ENFUVIRTIDE PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 43 GLOBAL GLUCAGON PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 44 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS 2013-2020 ($MILLION)
TABLE 45 GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY2013-2020 ($MILLION)
TABLE 46 GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY2013-2020 ($MILLION)
TABLE 47 GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 48 GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 49 GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 50 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2013-2020 ($MILLION)
TABLE 51 NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2013-2020 ($MILLION)
TABLE 52 EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)
TABLE 53 ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)
TABLE 54 LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2013-2020 ($MILLION)
LIST OF FIGURES
FIG. 1 TOP FACTORS IMPACTING BIOSIMILARS MARKET (2013-2020)
FIG. 2 TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2013)
FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS
FIG. 4 TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2013-2020
FIG. 5 KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
FIG. 6 REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
FIG. 7 PORTER’S FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
FIG. 8 VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
FIG. 9 MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2013)
FIG. 10 IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2013-2020-2025)
FIG. 11 SALES OF HGH BIOLOGICS IN UNITED STATES 2012
FIG. 12 IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2013-2020-2025)
FIG. 13 PROJECTED SALES OF EXPIRING PRODUCT IN UNITED STATES
FIG. 14 TOP 10 COMPANIES BLOCKBUSTER DRUGS REVENUE IN 2011 AND 2012
FIG. 15 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 16 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 17 SWOT ANALYSIS OF NOVARTIS (SANDOZ)
FIG. 18 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 19 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 20 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 21 NET REVENUE GENERATION (2011-2013)
FIG. 22 SWOT ANALYSIS OF LG LIFE SCIENCES
FIG. 23 NET PROFIT DURING 2011-2013
FIG. 24 SWOT ANALYSIS OF CELLTRION
FIG. 25 REVENUE GENERATED BY BUSINESS UNITS (2013)
FIG. 26 SWOT ANALYSIS OF BIOCON
FIG. 27 NET SALES BY GEOGRAPHY (2013)
FIG. 28 NET SALES BY BUSINESS UNITS (2013)
FIG. 29 SWOT ANALYSIS OF HOSPIRA
FIG. 30 NET SALES BY GEOGRAPHY (2013)
FIG. 31 NET SALES BY BUSINESS UNITS (2013)
FIG. 32 SWOT ANALYSIS OF MERCK SERONO
FIG. 33 NET SALES BY GEOGRAPHY (2013)
FIG. 34 NET SALES BY BUSINESS UNITS (2013)
FIG. 35 SWOT ANALYSIS OF BIOGEN IDEC INC.
FIG. 36 SWOT ANALYSIS OF GENENTECH
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
